Jas Khera is an accomplished Managing Director at WEP Clinical, where he leverages his extensive experience in the pharmaceuticals industry to drive innovative solutions in the realm of post-approval and pre-approval access programs. With a strong foundation in business development and a graduate degree from...
Jas Khera is an accomplished Managing Director at WEP Clinical, where he leverages his extensive experience in the pharmaceuticals industry to drive innovative solutions in the realm of post-approval and pre-approval access programs. With a strong foundation in business development and a graduate degree from The Manchester Metropolitan University, Jas excels in navigating the complexities of product commercialization and market access services. His leadership is pivotal in overseeing the Post Approval Named Patient Supply initiatives, ensuring that patients gain timely access to critical medications while adhering to regulatory frameworks.
Under Jas's guidance, WEP Clinical has successfully implemented expanded access programs that not only facilitate patient access but also gather invaluable real-world data. This data collection is essential for informing future clinical trials and enhancing pharmacovigilance support, ultimately contributing to safer and more effective healthcare solutions. His expertise in contract negotiation and sales operations has been instrumental in establishing strategic partnerships that enhance the company’s market presence and operational efficiency.
Jas's commitment to excellence is reflected in his ability to lead cross-functional teams, fostering a culture of collaboration and innovation. His skills in forecasting and sales effectiveness enable WEP Clinical to anticipate market trends and respond proactively, ensuring that the company remains at the forefront of the life sciences sector. As he continues to drive key projects that bridge the gap between pharmaceutical companies and healthcare providers, Jas Khera is not just shaping the future of access programs but is also making a significant impact on patient care across Europe.
